Biocryst Pharmaceuticals, Inc.
A biopharmaceutical company that develops medicines for rare diseases, BioCryst's flagship product is Orladeyo, an oral once-daily pill that prevents attacks of hereditary angioedema, a rare genetic condition causing sudden, painful swelling. Founded in 1986 in Birmingham, Alabama, the name blends "bio" with "cryst," a nod to the X-ray crystallography technique its scientists use to design drugs at the molecular level. The company also markets RAPIVAB, an antiviral treatment for influenza.
Granted 1.68M · Bought 30.0K · Sold 595.7K
Granted 819.2K · Bought 30.0K · Sold 6.1K
Granted 698.9K · Bought 5.0K · Sold 421.3K
Granted 263.7K · Bought 71.6K · Sold 5.7K
Granted 301.9K · Bought 30.0K · Sold 17.7K
Granted 197.0K · Sold 81.6K
Granted 268.7K
Granted 205.2K
Granted 76.0K · Bought 22.5K
Granted 24.0K
Granted 153.9K · Bought 5.0K · Sold 124.9K
Granted 64.2K · Bought 21.9K
Granted 193.1K · Sold 126.6K
Granted 71.7K · Bought 7.9K
Granted 38.0K · Bought 2.5K
Granted 59.6K · Sold 6.0K
Granted 67.0K · Sold 19.8K
Granted 64.2K · Sold 18.3K
Granted 183.3K · Sold 161.1K
Granted 127.4K · Sold 94.0K
Granted 35.5K
Granted 31.9K
Granted 22.6K · Sold 11.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Stonehouse Jon PDirector · 43 transactions | — | 2.84M | 1.68M | 30.0K | 595.7K |
| Gayer Charles KPresident and CCO · 16 transactions | +608.9% | 902.6K | 819.2K | 30.0K | 6.1K |
| Barnes Alane PChief Legal Officer · 23 transactions | +217% | 463.2K | 698.9K | 5.0K | 421.3K |
| Doyle AnthonyChief Financial Officer · 11 transactions | +599.8% | 377.9Kas of Dec 2024 | 263.7K | 71.6K | 5.7K |
| Thackray Helen M.Chief R&D Officer · 14 transactions | +277.3% | 377.3Kas of Mar 2025 | 301.9K | 30.0K | 17.7K |
| Babu Yarlagadda SChief Discovery Officer · 7 transactions | +60.5% | 330.1Kas of Nov 2022 | 197.0K | — | 81.6K |
| Ghias BabarChief Financial Officer · 2 transactions | — | 268.7K | 268.7K | — | — |
| Menon SandeepChief R&D Officer · 1 transaction | — | 205.2K | 205.2K | — | — |
| Milano VincentDirector · 23 transactions | +984.8% | 108.5K | 76.0K | 22.5K | — |
| Ingram Robert AlexanderDirector · 8 transactions | +31.5% | 100.2Kas of Feb 2023 | 24.0K | — | — |
| Hutson Nancy JDirector · 12 transactions | +35.1% | 99.1Kas of Jun 2025 | 153.9K | 5.0K | 124.9K |
| Galson Steven KDirector · 6 transactions | — | 86.2K | 64.2K | 21.9K | — |
| Heggie TheresaDirector · 23 transactions | +469.3% | 80.6K | 193.1K | — | 126.6K |
| Levin Alan GDirector · 14 transactions | — | 79.6K | 71.7K | 7.9K | — |
| Aselage SteveDirector · 8 transactions | — | 72.7Kas of Jun 2024 | 38.0K | 2.5K | — |
| Lee Kenneth B JrDirector · 5 transactions | +351.5% | 68.9Kas of Jun 2023 | 59.6K | — | 6.0K |
| McKee Amy EDirector · 11 transactions | — | 47.2K | 67.0K | — | 19.8K |
| Sanders MachelleDirector · 8 transactions | — | 45.9K | 64.2K | — | 18.3K |
| Sheridan William PChief Medical Officer · 4 transactions | +162.2% | 38.0Kas of Mar 2022 | 183.3K | — | 161.1K |
| Abercrombie George BDirector · 15 transactions | +355.4% | 36.4Kas of Jun 2024 | 127.4K | — | 94.0K |
| Frank StevenDirector · 8 transactions | — | 35.5K | 35.5K | — | — |
| Milne Jill C.Director · 5 transactions | — | 31.9K | 31.9K | — | — |
| Jones Michael LExec. Director, Finance - PAO · 7 transactions | +211.4% | 16.7Kas of Dec 2022 | 22.6K | — | 11.3K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.46M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.